T1LADE® Inhaler is indicated for maintenance therapy in the management of adult and pediatric patients 6 years and older with mild to moderate asthma. Important Safety Information: TILADE Inhaler is contraindicated in patients who have shown hypersensitivity to nedocromil sodium or other ingredients in this preparation. TILADE® Inhaler (nedocromil sodium inhalation aerosol) is not a bronchodilator and, therefore, should not be used for the reversal of acute bronchospasm, particularly status asthmaticus. The role of TILADE as a corticosteroid-sparing agent in patients receiving oral or inhaled corticosteroids remains to be defined. If systemic or inhaled corticosteroid therapy is reduced in patients receiving T1LADE , careful monitoring is necessary. Common adverse reactions include unpleasant taste, coughing, pharyngitis, rhinitis, upper respiratory in fection, bronchospasm, and headache.
Tags:
No comments:
Post a Comment